FDA panel backs Takeda's gout drug Uloric for some patient populations

A joint FDA advisory panel voted 19-2, with one abstention, that gout drug Uloric febuxostat has a favorable benefit-risk profile for

Read the full 214 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE